Dupilumab Outperforms Omalizumab in First Head-to-Head Trial for Severe CRSwNP with Asthma: Study
The EVEREST trial directly compared biologics in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma, and found that dupilumab (Dupixent) was superior to omalizumab (Xolair). At week 24, dupilumab achieved better results across all primary and secondary efficacy endpoints. The findings were published in the recent issue Lancet Respiratory Medicine. CRSwNP is a chronic […]